Masimo Corporation

Masimo (NASDAQ: MASI) is a global medical technology company that develops and manufactures innovative noninvasive patient monitoring technologies, including medical devices and a wide array of sensors. Masimo is committed to improving patient outcomes and reducing cost of care by working with dedicated hospital staff to convert healthcare institutions around the world to Masimo SET pulse oximetry technology. We are accomplishing this goal through partnering with our patient monitoring companies and caregivers and creating innovative, cost-effective acquisition programs for Masimo SET products for the benefit of the patients. A key medical technology innovator, Masimo is responsible for the invention of award-winning noninvasive technologies that are revolutionizing patient monitoring, including Masimo SET® pulse oximetry, Masimo Rainbow Pulse CO-Oximetry and new Masimo noninvasive and continuous total hemoglobin (SpHb™) monitoring technology. The recent introduction of the first-and-only FDA-cleared technology that noninvasively and continuously measures total hemoglobin without a painful needle stick and invasive blood draw is expected to open new markets and significantly expand the company’s growth opportunities. For more than 20 years now, Masimo has been focused on a singular mission — to create noninvasive patient monitoring technologies that are more effective and reliable and to improve patient outcomes and reduce the cost of care by bringing these technologies to new sites and applications. The result is a portfolio of clinically-proven products that lead the way in innovation, performance and patient safety by giving health care providers the information they need to optimize clinical decision-making.

Irvine, US
Size (employees)
1,243 (est)-4%
Masimo Corporation was founded in 1989 and is headquartered in Irvine, US

Masimo Corporation Office Locations

Masimo Corporation has offices in Irvine, Washington, Cleveland, Singapore and in 27 other locations
Irvine, US (HQ)
52 Discovery

Masimo Corporation Data and Metrics

Masimo Corporation Financial Metrics

Masimo Corporation's revenue was reported to be $663.8 m in FY, 2016 which is a 5% increase from the previous period.
$, USD

Revenue (FY, 2016)

663.8 m

Revenue growth (FY, 2015 - FY, 2016), %


Net income (FY, 2016)

300.7 m

EBIT (FY, 2016)

103.5 m

Market capitalization (23-Jun-2017)

4.8 b

Closing share price (23-Jun-2017)


Cash (31-Dec-2016)

306 m


4.7 b
Masimo Corporation's current market capitalization is $4.8 b.
$, USDFY, 2015FY, 2016


630.1 m663.8 m

Revenue growth, %


General and administrative expense

252.7 m241 m

Operating expense total

252.7 m241 m


120.3 m103.5 m

EBIT margin, %


Net Income

81.5 m300.7 m
$, USDFY, 2015FY, 2016


132.3 m306 m


62 m72.5 m

Current Assets

299.1 m507.2 m


132.5 m136 m


20.4 m19.8 m

Total Assets

601.7 m820.5 m

Accounts Payable

25.9 m31.1 m

Total Debt

125.2 m185.2 m

Current Liabilities

132.6 m220.4 m

Additional Paid-in Capital

332.4 m382.3 m

Retained Earnings

288.6 m589.2 m

Total Equity

275.7 m560.2 m

Debt to Equity Ratio

0.5 x0.3 x

Debt to Assets Ratio

0.2 x0.2 x

Financial Leverage

2.2 x1.5 x
$, USDFY, 2015FY, 2016

Net Income

81.5 m300.7 m

Depreciation and Amortization

15.7 m16.8 m

Accounts Receivable

(9.9 m)(21 m)

Accounts Payable

(4.3 m)7.8 m

Cash From Operating Activities

114.2 m416.8 m

Purchases of PP&E

(50.4 m)(19.7 m)

Cash From Investing Activities

(54.6 m)(25.1 m)

Short-term Borrowings

(80 k)(75 k)

Cash From Financing Activities

(59.1 m)(216.6 m)
$, USDY, 2016


45.2 x


11.2 x


510.7 k


0.3 x


0.2 x

Financial Leverage

1.5 x

Masimo Corporation Operating Metrics

FY, 2016

Patents Issued


Patents Pending


Masimo Corporation Market Value History

Masimo Corporation Revenue Breakdown

Masimo Corporation Job Categories

Masimo Corporation Median Salaries

Source: 56 public H-1B filings from Masimo Corporation

Masimo Corporation Online and Social Media Presence

Masimo Corporation Company Life and Culture

You may also be interested in